Activity of pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in combination with crizotinib in ovarian cancer xenografts and PDX

Alice Iezzi, Elisa Caiola, Massimo Broggini

Research output: Contribution to journalArticlepeer-review

Abstract

The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often deregulated in cancer. The two pathways are interconnected and at least c-Met has been implicated in drug resistance. The aim of the study was to assess in ovarian cancer preclinical models, the efficacy and tolerability of a dual PI3K mTOR inhibitor (PF-05212384 or gedatolisib) and a c-Met inhibitor (crizotinib) either as single agents or in combination. In vitro, both PF-05212384 and crizotinib showed a concentration dependent activity in the two ovarian cancer cell lines. The combination of the two did not result in synergistic activity. A subline resistant to gedatolisib was obtained and showed an increased expression of MDR-1 gene. In vivo results show that crizotinib alone did not display any activity in all the tumors investigated, while PF-05212384 alone had some marginal activity. The combination of the two resulted in all the experiments superior to single agents with a good tolerability. Considering that crizotinib did not show activity in the models used, the results indicate that crizotinib is able to potentiate the activity of PF-05212384. Although the activity of the combination was not striking in these three models of ovarian cancer, due to the good tolerability of the combination, the results would suggest the possibility to combine the two drugs in settings in which gedatolisib or crizotinib alone have already some significant activity.

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalTranslational Oncology
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 1 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Activity of pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in combination with crizotinib in ovarian cancer xenografts and PDX'. Together they form a unique fingerprint.

Cite this